Windtree Therapeutics Files Q1 2025 10-Q
Ticker: WINTW · Form: 10-Q · Filed: May 15, 2025 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: 10-Q, financing, biotech, loss
TL;DR
Windtree Therapeutics Q1 2025: Minimal revenue, big losses, $120M note issued.
AI Summary
Windtree Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal revenue and significant operating expenses, with a net loss for the quarter. Key financial activities include a $120 million convertible promissory note issuance and a $3.56 million Eloc Purchase Agreement.
Why It Matters
This filing provides insight into Windtree Therapeutics' financial health and ongoing operational activities, which could impact its stock price and investor confidence.
Risk Assessment
Risk Level: high — The company has minimal revenue and significant operating losses, indicating a high risk of financial instability.
Key Numbers
- $0.001 — Revenue (Minimal revenue reported for Q1 2025.)
- $120,000,000 — Convertible Promissory Note (Represents a significant financing activity.)
- $3,555,954 — Eloc Purchase Agreement (Indicates a financing or transaction related to Eloc.)
- $256,397 — Net Loss (Indicates the company's profitability for the period.)
Key Players & Entities
- WINDTREE THERAPEUTICS INC /DE/ (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250515 (date) — Filing Date
- $120,000,000 (dollar_amount) — Convertible Promissory Note Issuance
- $3,555,954 (dollar_amount) — Eloc Purchase Agreement
FAQ
What is the total revenue for the quarter ending March 31, 2025?
The total revenue for the quarter ending March 31, 2025, was $0.001.
What was the net loss for the quarter ending March 31, 2025?
The net loss for the quarter ending March 31, 2025, was $256,397.
What is the principal amount of the convertible promissory note issued?
The principal amount of the convertible promissory note issued is $120,000,000.
What was the value of the Eloc Purchase Agreement as of March 31, 2025?
The value of the Eloc Purchase Agreement as of March 31, 2025, was $3,555,954.
What was the company's previous name before Windtree Therapeutics Inc.?
The company was formerly known as Discovery Laboratories Inc. /DE/.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding WINDTREE THERAPEUTICS INC /DE/ (WINTW).